{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["McSkane M"],"funding":["NCI NIH HHS"],"pagination":["215-222.e3"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7496217"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["17(3)"],"pubmed_abstract":["<h4>Background</h4>Previous studies have found significant relationships between height and colorectal cancer (CRC) risk. Increased growth has been associated with activated pathways such as insulin-like growth factor 1. This study examined the impact of height on outcomes in metastatic CRC patients enrolled onto the FIRE-3 study, a randomized phase 3 clinical trial.<h4>Patients and methods</h4>A total of 695 patients with metastatic CRC were studied and height was measured in centimeters. Male patients were grouped as ≤ 165, 166-175, 176-185, and ≥ 186 cm in height; female patients were grouped as ≤ 154, 155-164, 165-174, and ≥ 175 cm in height. Primary end point was overall survival (OS); secondary end point was progression-free survival.<h4>Results</h4>When patients' heights were catego"],"journal":["Clinical colorectal cancer"],"pubmed_title":["Association Between Height and Clinical Outcome in Metastatic Colorectal Cancer Patients Enrolled Onto a Randomized Phase 3 Clinical Trial: Data From the FIRE-3 Study."],"pmcid":["PMC7496217"],"funding_grant_id":["P30 CA014089"],"pubmed_authors":["Puccini A","Heinemann V","Stintzing S","Lenz HJ","McSkane M","Cao S","Jelas I","Naseem M"],"additional_accession":[]},"is_claimable":false,"name":"Association Between Height and Clinical Outcome in Metastatic Colorectal Cancer Patients Enrolled Onto a Randomized Phase 3 Clinical Trial: Data From the FIRE-3 Study.","description":"<h4>Background</h4>Previous studies have found significant relationships between height and colorectal cancer (CRC) risk. Increased growth has been associated with activated pathways such as insulin-like growth factor 1. This study examined the impact of height on outcomes in metastatic CRC patients enrolled onto the FIRE-3 study, a randomized phase 3 clinical trial.<h4>Patients and methods</h4>A total of 695 patients with metastatic CRC were studied and height was measured in centimeters. Male patients were grouped as ≤ 165, 166-175, 176-185, and ≥ 186 cm in height; female patients were grouped as ≤ 154, 155-164, 165-174, and ≥ 175 cm in height. Primary end point was overall survival (OS); secondary end point was progression-free survival.<h4>Results</h4>When patients' heights were catego","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018 Sep","modification":"2025-04-04T01:37:00.484Z","creation":"2020-09-20T07:01:32Z"},"accession":"S-EPMC7496217","cross_references":{"pubmed":["29880436"],"doi":["10.1016/j.clcc.2018.05.003"]}}